Duke University researchers have developed a small interfering RNA therapy that silences a key gene in lysine metabolism, offering a potential twice-yearly injectable alternative to lifelong dietary restriction.

A gene-silencing treatment targeting the liver has shown preclinical promise against glutaric aciduria type I (GA1), a rare inherited metabolic disorder that can cause irreversible neurological damage in children.
Researchers at Duke University School of Medicine developed a small interfering RNA (siRNA) therapy that reduces the production of toxic metabolic byproducts responsible for brain injury. When using mouse models, the treatment improved survival, reduced the accumulation of harmful substances and protected against neurological damage, even when animals were fed high-protein diets.
Targeting the source of toxic metabolites
GA1 occurs when the body cannot properly break down the essential amino acid lysine. This leads to the accumulation of toxic metabolic byproducts, which can enter the brain and damage areas responsible for controlling movement.
Although every newborn in the United States is screened for the condition, current management relies primarily on a low-lysine diet and emergency interventions during acute illness. Despite these measures, around a third of patients develop severe movement disorders and some complications can be fatal.
The research team, led by Karl-Dimiter Bissig, a paediatric researcher and Chen Family Associate Professor of Pediatrics at Duke, investigated whether targeting the liver could prevent the production of the harmful metabolites before they reach the brain.
The approach builds on previous research by Bissig and collaborators, which demonstrated in 2023 that the liver was the source of the toxic compounds responsible for neurological damage. This challenged the previous focus on the brain as the primary site of the disease.
“There are these connections within the body, particularly through metabolism,” said Bissig. “The liver is connected with every single organ.”
Using this understanding, the researchers developed an siRNA therapy designed to silence a gene involved in lysine breakdown, reducing the production of the toxic substances.
Improved survival in mouse models
The team tested the treatment in adult and neonatal mouse models of GA1. All adult mice receiving the therapy survived, while neonatal mice treated with siRNA also demonstrated improved survival compared with controls, despite being fed high-protein diets.
Analysis of tissue samples revealed significant reductions in metabolic byproducts, including those found in the brain. Importantly, the researchers found no evidence of brain injury in treated animals.
The investigation also identified potential biomarkers in blood plasma that were associated with neurological outcomes. These could provide a way to monitor disease progression and assess responses to treatment in future studies.
“What we have now is a translational approach, it gives us hope,” said Bissig.
Potential alternative to restrictive diets
The researchers believe the findings could offer a new way to manage GA1 without relying so heavily on strict dietary restrictions.
Bissig now hopes to progress the work towards clinical trials, using siRNA as a non-permanent approach to gene silencing. As several siRNA medicines targeting the liver are already approved, this will provide an established therapeutic framework for further development.
If successful, the treatment could significantly reduce the daily burden of managing the condition.
“You could inject patients two or three times a year, and they’re protected 24-7, imagine how easy that therapy could be,” said Bissig.



No comments yet